Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WNV diagnostics

This article was originally published in The Gray Sheet

Executive Summary

FDA issues a 1Class II special controls guidance for WNV assays Oct. 30 in the wake of PanBio's Capture lab test de novo 510(k) clearance (2"The Gray Sheet" July 14, 2003, p. 21). The guidance addresses premarket requirements for the WNV IgM Elisa assay, including labeling and performance study information...

You may also be interested in...



West Nile Virus: FDA Clears PanBio Test, Canada Okays Roche Blood Screen

The de novo 510(k) route pursued by PanBio for its Capture West Nile virus clinical lab test could set a precedent for expedited approvals of diagnostics to detect emerging diseases

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

China Uses Old To Fight New As Repurposed Drugs Take Coronavirus Role

Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.

UsernamePublicRestriction

Register

MT019274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel